🧬 BIOTECH CATALYST AI SCANNER — November WK1

I have significantly upgraded the catalyst scanner by integrating advanced machine learning algorithms that operate on static datasets and incorporating AI-driven features for greater analytical depth and quality. While these technological enhancements improve the scanner’s coverage and insight, it’s important to note that AI functions solely as a tool and cannot independently verify information. Readers are strongly encouraged to perform their own due diligence before acting on any findings.

Please note: The catalyst scanner is intended to identify biotech companies with catalysts expected within a 10 to 45-day window and may not be suitable for those focused on long-term, fundamentals-based investing. Additionally, the tier system is provided for reference only and does not predict success rates. In biotech, significant price movements often come from unexpected candidates, and highly anticipated investments frequently disappoint investors.

Weekly updates are published every Thursday or Friday, offering readers timely opportunities to review new data and conduct deeper research over the weekend.

Report Date: Friday, October 31, 2025
Analysis Period: November-December 2025 Catalysts
Methodology: ML Screening + AI Verification + 4-Factor Scoring Framework

⚠️ Disclaimer

Not Financial Advice: This report provides data analysis only. It does not constitute financial, investment, or medical advice. Biotech investments carry substantial risk including potential total loss. Conduct your own due diligence and consult qualified professionals before making any investment decisions.

Catalyst Dates Are Estimates: FDA PDUFA dates can shift, conference presentations may be rescheduled, and company guidance can change. Always verify dates independently before making decisions.

Automated System: This report is generated through an automated machine learning and AI verification system. The publisher has no control over the screening results, scoring, or rankings. The system analyzes historical catalyst data (15+ years), technical indicators, and publicly available information to identify potential opportunities.

🎯 Executive Summary

Candidates Analyzed: 22
Published in Detail: 9 top opportunities (1 Tier A+, 3 Tier A, 5 Tier B highlights)
Also Tracked: 13 additional candidates monitored but below publication threshold

This week's analysis reveals a concentrated opportunity set with several near-term PDUFA decisions and high-quality conference presentations. The standout remains KURA's November 30 menin inhibitor decision, though Syndax's October 24 approval of Revuforj for NPM1-mutated AML significantly alters the competitive landscape. The Tier A cohort features three well-positioned binary catalysts with strong financial backing.

Key Themes:

• Multiple imminent PDUFA decisions (Nov 18-Dec 20 window)
• Strong ASH 2025 representation (Dec 6-9) with CAR-T and hematology data
• Rare disease focus: AL amyloidosis, achondroplasia, hypothalamic obesity
• Competitive dynamics shift: Syndax's recent menin inhibitor approval impacts KURA
• Competitive PDUFA cluster mid-December

🏆 Tier A+ Opportunities

KURA - Kura Oncology Inc.

Price: $10.44 | Cap: $906M | Cash: ~$621M | Runway: 36 mo+
Catalyst: PDUFA November 30, 2025
Drug: Ziftomenib (Menin Inhibitor) | Indication: Relapsed/Refractory AML
Enriched Score: 9.05/10

Why This Matters:
Ziftomenib is an oral menin inhibitor targeting R/R AML patients with KMT2A rearrangements or NPM1 mutations—the same genetic drivers addressed by Syndax's recently-approved Revuforj (revumenib). The November 30 PDUFA marks a critical decision point as KURA seeks to enter a market where a competitor gained first-mover advantage just days ago.

The Competitive Reality:
On October 24, 2025, Syndax received FDA approval for Revuforj in NPM1-mutated R/R AML, expanding their 2024 approval for KMT2A-rearranged acute leukemia. Revuforj is now the first and only menin inhibitor approved for both indications that ziftomenib targets. This fundamentally changes Kura's commercial landscape—from potential first-in-class to second-to-market entrant facing an established competitor.

Clinical Differentiation Becomes Critical:
The Phase 1/2 KOMET-001 trial data must now demonstrate clear advantages over Revuforj to justify market share. The FDA granted Breakthrough Therapy Designation based on response rates in the KMT2A and NPM1 populations, suggesting the clinical profile is competitive. Ziftomenib's oral formulation matches Revuforj's convenience, so differentiation will likely come from safety profile, response durability, or efficacy in specific subpopulations.

The November 30 Decision:
The FDA must now evaluate ziftomenib knowing Revuforj is approved and commercially available. The Agency will likely scrutinize whether ziftomenib offers meaningful differentiation. Kura's challenge: demonstrate that a second menin inhibitor provides patient benefit beyond what Revuforj delivers. The BTD designation suggests the FDA sees value, but approval is no longer a certainty given the changed competitive dynamics.

Commercial and Financial Considerations:
Even with approval, Kura faces a formidable market entry challenge. Syndax has built relationships with hematology-oncologists, established payer coverage, and gained clinical experience over the past year. Kura's strong balance sheet (over 5 years runway) provides staying power for commercial execution, but the path to meaningful market penetration is now significantly harder.

Market Positioning:
The stock's neutral technical setup (RSI 54.8, minimal momentum) suggests the October 24 Syndax approval hasn't been fully digested by KURA investors. The $906M market cap may be pricing in optimistic market share assumptions that need reassessment given the competitive reality.

Updated Risk Assessment:
Beyond standard regulatory risk, Kura now faces commercial execution risk even if approved. Can a second-to-market menin inhibitor gain traction when physicians have an established option? The November 30 PDUFA remains a binary catalyst, but the upside case requires stronger differentiation than previously assumed. Label differences, head-to-head data, or superior tolerability could create opportunities, but these factors remain uncertain.

⭐ Tier A Opportunities

ARWR - Arrowhead Pharmaceuticals Inc.

Price: $42.31 | Cap: $5.85B | Cash: ~$1,219M | Runway: 20 mo+
Catalyst: PDUFA November 18, 2025 (17 days)
Drug: Plozasiran (RNAi Therapy) | Indication: Familial Chylomicronemia Syndrome / Severe Hypertriglyceridemia
Enriched Score: 8.85/10

The Opportunity:
Plozasiran is an RNAi therapeutic targeting APOC3 for patients with familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia—conditions with limited treatment options and high risk of pancreatitis. The November 18 PDUFA date is imminent, providing a near-term binary catalyst.

Clinical Differentiation:
The Phase 3 PALISADE trial data showed substantial triglyceride reductions with quarterly dosing, addressing a significant unmet need. Plozasiran's mechanism directly silences APOC3 production in the liver, offering durable efficacy without the daily pill burden of current therapies. The safety profile appears clean in completed studies.

Technical and Financial Context:
ARWR maintains positive momentum (7.3% over 21 days) and neutral RSI (50.2), suggesting the market hasn't overextended ahead of the decision. With nearly 2 years of runway and a strong balance sheet, Arrowhead can support a full commercial launch. The large market cap ($5.85B) reflects Arrowhead's broader RNAi platform, providing downside support even if this specific approval faces challenges.

Why November 18 Matters:
This is the first major RNAi therapy decision in the cardiometabolic space from Arrowhead, potentially validating the platform for multiple future indications. Approval would de-risk the entire pipeline and open partnership opportunities for other APOC3-related programs.

RYTM - Rhythm Pharmaceuticals Inc.

Price: $111.81 | Cap: $7.43B | Cash: $456.7M | Runway: 36 mo+
Catalyst: PDUFA December 20, 2025
Drug: Setmelanotide (MC4R Agonist) | Indication: Hypothalamic Obesity
Enriched Score: 8.48/10

The Thesis:
Rhythm seeks to expand setmelanotide's label to acquired hypothalamic obesity (aHO), a devastating complication following brain surgery or injury. Current standard of care is essentially non-existent, making this a true orphan opportunity with high unmet need.

TRANSCEND Data:
The pivotal Phase 3 trial demonstrated a remarkable 19.8% placebo-adjusted BMI reduction in aHO patients aged 4+ years. These results far exceed what's typically seen with lifestyle interventions or even GLP-1 agonists in this population. Importantly, hunger scores improved significantly, addressing a core symptom that dramatically impacts patient quality of life.

Strategic Context:
Setmelanotide is already approved for genetic obesity syndromes (POMC, PCSK1, LEPR deficiencies), and this label expansion leverages the same mechanism while opening a substantially larger patient population. The MC4R pathway's role in hypothalamic obesity is well-validated scientifically, reducing regulatory risk.

Financial and Market Position:
Rhythm's nearly 5-year cash runway and positive momentum (11.8% over 21 days) reflect confidence in the approval trajectory. The RSI of 63.0 shows enthusiasm but not extreme overbought conditions. The large market cap provides both upside potential and downside protection.

MIST - Milestone Pharmaceuticals Inc.

Price: $1.88 | Cap: $160M | Cash: ~$154M | Runway: 36 months+
Catalyst: PDUFA December 13, 2025
Drug: CARDAMYST (Etripamil) | Indication: Paroxysmal Supraventricular Tachycardia (PSVT)
Enriched Score: 8.28/10

The Redemption Story:
CARDAMYST received a Complete Response Letter (CRL) in March 2025 citing manufacturing and nitrosamine testing issues—notably, not clinical concerns. Milestone quickly addressed these CMC matters, and the FDA accepted their response in July, setting the December 13 PDUFA. This represents a classic CRL-to-approval setup.

Clinical Value Proposition:
The Phase 3 RAPID trial demonstrated that etripamil nasal spray achieved 64% conversion of PSVT episodes to normal rhythm within 30 minutes, compared to 31% with placebo. For patients experiencing sudden-onset rapid heart rates, a self-administered nasal spray bypassing emergency rooms represents a paradigm shift. Current standard of care requires IV adenosine in medical settings, making this a true innovation in patient autonomy.

What Changed:
Milestone conducted additional nitrosamine studies per updated FDA guidance and resolved manufacturing facility inspection issues. The FDA's acceptance of the response and willingness to set a new PDUFA date suggest these were addressable technical matters rather than fundamental product concerns.

Capital Structure Transformation:
The company raised up to $170 million in a public offering in July-August 2025 and extended its $75 million Royalty Purchase Agreement with RTW through December 31. This war chest provides 36+ months of runway and ensures Milestone can execute a full commercial launch if approved. The pre-launch infrastructure remains intact from the original March PDUFA preparation.

Market Dynamics:
At $160M market cap, MIST trades at a valuation that heavily discounts approval probability despite the addressed CRL. The negative 21-day momentum (-8.3%) and neutral RSI (45.1) suggest positioning hasn't crowded ahead of the decision. This creates asymmetric upside if approval comes through, with limited incremental downside given the capital raise.

Risk Assessment:
The FDA could identify additional manufacturing concerns or request more data, but the acceptance of the resubmission and assignment of a Class 2 review (6-month timeline) indicate the Agency views the responses as adequate. Competitive risk is minimal—no approved self-administered PSVT treatments exist.

📌 Tier B Highlights (Top 5 of 10)

AXGN - Axogen Inc.

Price: $22.68 | Cap: $1.05B | Cash: Runway 34 months
Catalyst: PDUFA December 5, 2025
Drug: Avance Nerve Graft | Indication: Severed Peripheral Nerves
Score: 7.90/10

Axogen seeks approval for its processed nerve allograft in peripheral nerve repair, based on the RECON trial data. The nerve repair market is specialized but clinically significant, and Avance represents a biological solution avoiding autograft harvesting. With strong capitalization (34 months runway) and a binary PDUFA catalyst, this offers a clean approval catalyst in a niche market. The large market cap ($1.05B) limits volatility but provides stability. Neutral technicals and strong execution context support the setup.

AGIO - Agios Pharmaceuticals Inc.

Price: $43.18 | Cap: $2.51B | Cash: Runway 30 months
Catalyst: PDUFA December 7, 2025
Drug: PYRUKYND (Mitapivat) | Indication: Thalassemia
Score: 7.90/10

Mitapivat is already approved for pyruvate kinase deficiency, and Agios now seeks label expansion to thalassemia based on the ENERGIZE trial. The pyruvate kinase activation mechanism addresses hemolysis and reduces transfusion burden—a meaningful clinical benefit in thalassemia patients. With strong cash reserves (31 months) and neutral market positioning, AGIO offers a lower-risk label expansion catalyst. The $2.5B market cap reflects the established commercial infrastructure for PYRUKYND, enabling rapid label expansion execution if approved.

INVA - Innoviva Inc.

Price: $17.95 | Cap: $1.13B | Cash: Runway 36 months+
Catalyst: PDUFA December 15, 2025
Drug: Zoliflodacin | Indication: Uncomplicated Gonorrhea
Score: 7.88/10

Zoliflodacin is a novel oral antibiotic addressing rising antibiotic resistance in gonorrhea treatment—a significant public health concern. As the first new mechanism in this indication in years, zoliflodacin benefits from FDA and public health urgency around antibiotic resistance. The recent momentum has been negative (-5.0% over 21 days), potentially creating an attractive entry point ahead of the mid-December decision. Innoviva's strong balance sheet (38 months runway) enables full commercialization without dilution risk.

BCRX - BioCryst Pharmaceuticals Inc.

Price: $7.25 | Cap: $1.52B | Cash: Runway 22 months
Catalyst: PDUFA December 12, 2025
Drug: ORLADEYO (Berotralstat) | Indication: Pediatric Hereditary Angioedema (HAE)
Score: 7.88/10

BioCryst's oral kallikrein inhibitor ORLADEYO is already approved for adult HAE prophylaxis. The pediatric expansion targets patients aged 2-11 years, a label extension with lower regulatory risk than novel drug approvals. The APeX-P trial demonstrated efficacy and safety in the pediatric population. BioCryst's commercial infrastructure is already built, enabling rapid pediatric launch if approved. The December 12 PDUFA provides a binary catalyst with favorable risk-reward given the precedent of adult approval.

APVO - Aptevo Therapeutics Inc.

Price: $1.4 | Cap: $4.6M | Cash: Runway <3mo (critical)
Catalyst: ASH Presentation December 6-9, 2025
Drug: Mipletamig + Venetoclax/Azacitidine | Indication: Frontline AML
Score: 7.55/10

High Risk, High Reward:
Aptevo's mipletamig is the star of this week's clinical data stories, achieving 100% complete remission in Cohort 3 of the RAINIER trial and 85-90% remission rates overall in frontline AML patients unfit for intensive chemotherapy. The CD123 x CD3 bispecific antibody uses a proprietary CRIS-7 binding domain that has eliminated cytokine release syndrome (CRS)—a major safety hurdle for bispecific therapies. The data outperform venetoclax + azacitidine alone (66% remission in Viale-A) and position mipletamig as a potentially transformative frontline therapy.

The ASH Catalyst:
Aptevo will present interim RAINIER Phase 1b/2 results at ASH 2025 (December 6-9) in Orlando. This is not virgin data—the company has released multiple updates throughout 2025—but the formal ASH presentation consolidates the dataset and provides visibility among hematologists. The conference setting could catalyze partnership interest or acquisition discussions.

Critical Funding Situation:
The major caveat is Aptevo's cash position. Multiple small raises throughout 2025 ($2M, $2.1M, $8M, $15.9M) have extended runway, but the company is in a constant fundraising mode. The micro-cap valuation ($4.6M) reflects this precarious financial situation. Recent strong momentum (76.4% over 21 days) and elevated RSI (70.25) indicate enthusiasm for the clinical data but also suggest overbought conditions.

The Investment Calculus:
If mipletamig data continues to impress and Aptevo secures partnership or acquisition interest, the micro-cap could re-rate dramatically. However, dilution risk is extreme, and without near-term capital, the company may struggle to advance RAINIER through registration-enabling studies. This is a high-risk, high-potential-reward situation suitable only for investors comfortable with binary outcomes and dilution.

📋 Additional Candidates Tracked

The following 13 candidates were analyzed but scored below our detailed publication threshold. These remain on our radar for monitoring:

Remaining Tier B Candidates (5)

IMMX - Immix Biopharma Inc.
Price: $3.67 | Market Cap: $106M | Cash Runway: 2 months
Score: 7.53 | Catalyst: ASH Presentation, December 6-9, 2025

• NXC-201 CAR-T therapy for relapsed/refractory AL amyloidosis
• Strong clinical data: 75% complete response rate, FDA RMAT designation
• Only CAR-T in development for this orphan indication
• Major concern: Critical cash runway situation requires immediate funding
• Despite excellent clinical profile, financial constraints limit near-term upside

MTVA - MetaVia Inc.
Price: $0.97 | Market Cap: $24M | Cash Runway: 13.1 months
Score: 7.50 | Catalyst: AASLD Poster, November 10, 2025

• Vanoglipel (DA-1241) GPR119 agonist for MASH
• Phase 2a data already reported showing hepatoprotective effects
• Conference presentation is recap, not virgin data
• Adequate cash runway through near-term milestones
• Competitive MASH landscape requires strong differentiation

IMMP - Immutep Limited
Price: $1.92 | Market Cap: $283M | Cash Runway: 15 months
Score: 7.43 | Catalyst: ASH Conference, December 12, 2025

• Eftilagimod alpha (LAG-3 agonist) with paclitaxel for metastatic breast cancer
• Phase 2/3 AIPAC-003 trial data presentation
• Competitive MBC landscape with multiple checkpoint inhibitors
• Strong cash position supports continued development
• Larger market cap provides downside protection

ALDX - Aldeyra Therapeutics Inc.
Price: $5.03 | Market Cap: $301M | Cash Runway: 24 months
Score: 7.38 | Catalyst: PDUFA, December 16, 2025

• Reproxalap (RASP inhibitor) for dry eye disease
• Prior Complete Response Letter creates regulatory uncertainty
• CHAMBER trial data supports resubmission
• Well-funded with 2+ years of runway
• Highly competitive dry eye market with multiple approved therapies

OSTX - OS Therapies Incorporated
Price: $1.77 | Market Cap: $56M | Cash Runway: 9 months
Score: 7.00 | Catalyst: End of Phase Meeting, December 11, 2025

• OST-HER2 for resected osteosarcoma
• Orphan indication with high unmet need
• Limited publicly available clinical data
• Moderate cash runway adequate for near-term milestone
• Potential BLA filing pathway discussion with FDA

Tier C Candidates (7)

IFRX - InflaRx N.V.
Price: $1.32 | Market Cap: $78M | Cash Runway: 14 months
Score: 6.50 (Vilobelimab) / 6.35 (INF904) | Catalyst: Phase 2 Topline Data, November 30, 2025

• Vilobelimab (IFX-1): C5a inhibitor in Phase 2 for hidradenitis suppurativa; established safety profile from other indications
• INF904: Phase 2a readout in chronic autoimmune/inflammatory diseases; early-stage mechanism validation
• Company has two distinct November 30 catalysts with same compound class
• Dual readouts provide multiple shots on goal but increase complexity

ASND - Ascendis Pharma A/S
Price: $203.71 | Market Cap: $12.4B | Cash Runway: Strong
Score: 6.48 | Catalyst: PDUFA, November 30, 2025

• TransCon CNP for achondroplasia in children
• Positive efficacy data on growth velocity and height
• FDA previously flagged patient death (causality unclear) and manufacturing issues
• Large-cap provides stability but limits volatility
• Regulatory uncertainty from prior concerns

BMY - Bristol-Myers Squibb Company
Price: $45.62 | Market Cap: $92.9B | Cash Runway: Strong
Score: 6.28 | Catalyst: PDUFA, December 5, 2025

• Breyanzi (liso-cel) CAR-T label expansion to marginal zone lymphoma
• Already approved product seeking additional indication
• Mega-cap structure means minimal stock impact from approval
• Strong commercial infrastructure for rapid launch if approved

LPCN - Lipocine Inc.
Price: $2.60 | Market Cap: $14M | Cash Runway: 24 months
Score: 6.03 | Catalyst: Conference Presentation, December 7, 2025

• LPCN 2101 in Phase 2 for epilepsy
• Early-stage program with limited public data
• Micro-cap with high volatility potential
• Strong runway relative to market cap provides development cushion

ONCY - Oncolytics Biotech Inc.
Price: $1.16 | Market Cap: $116M | Cash Runway: 3 months
Score: 5.95 | Catalyst: End of Phase Meeting, November 30, 2025 (vague date)

• Pelareorep oncolytic virus platform in PDAC combination therapy
• Interesting immunotherapy mechanism but early-stage data
• Critical cash runway issue (<4 months) requires immediate financing
• Negative momentum (-18.3%) reflects funding concerns

MNOV - MediciNova Inc.
Price: $1.19 | Market Cap: $58M | Cash Runway: 36 months+
Score: 5.68 | Catalyst: Conference Presentation, December 5, 2025

• Ibudilast (MN-166) in Phase 2b/3 COMBAT-ALS trial for ALS
• No new data expected at December conference
• Trial fully enrolled but data maturity expected late 2026
• Exceptional cash runway (6+ years) but low near-term catalysts
• Showed notable upward momentum at the time the scan was performed.

AMGN - Amgen Inc.
Price: $292 | Market Cap: $157B | Cash Runway: Strong
Score: 5.73 | Catalyst: PDUFA, December 14, 2025

• Uplizna (inebilizumab) for myasthenia gravis
• Label expansion for already-approved product
• Mega-cap structure eliminates meaningful volatility from approval
• Competitive myasthenia gravis treatment landscape

📅 Catalyst Timeline

November 2025:

• Nov 10: MTVA (AASLD MASH poster)
• Nov 18: ARWR (Plozasiran PDUFA) ⭐
• Nov 30: KURA (Ziftomenib PDUFA) 🏆 | ONCY, IFRX (x2), ASND (various)

December 2025:

• Dec 5: AXGN (PDUFA), BMY (PDUFA), MNOV (Conference)
• Dec 6-9: APVO, IMMX, IMMP (ASH Presentations)
• Dec 7: AGIO (PDUFA), LPCN (Conference)
• Dec 11: OSTX (End of Phase)
• Dec 12: BCRX (PDUFA), IMMP (Conference)
• Dec 13: MIST (PDUFA) ⭐
• Dec 14: AMGN (PDUFA)
• Dec 15: INVA (PDUFA)
• Dec 16: ALDX (PDUFA)
• Dec 20: RYTM (PDUFA) ⭐

💭 Final Perspective

This week's analysis highlights a concentrated window of high-quality catalysts spanning mid-November through late December. KURA's menin inhibitor PDUFA on November 30 remains a significant catalyst, though Syndax's October 24 approval of Revuforj fundamentally changed the competitive equation from potential first-in-class to second-to-market. The Tier A cohort of ARWR, RYTM, and MIST all offer compelling risk-reward setups with near-term binary catalysts and strong financial positioning.

Key risks across the opportunity set include execution challenges for undercapitalized micro-caps (APVO, IMMX, ONCY), competitive dynamics in crowded indications (IMMP in MBC, ALDX in dry eye, KURA facing Syndax), and regulatory uncertainty for companies with prior CRLs or FDA concerns.

The 9 candidates published in detail represent the highest-conviction opportunities identified by our ML+AI verification system. Readers interested in deeper analysis of the additional 13 tracked candidates should conduct their own due diligence or leave a comment for a request for an expanded research.

Next Catalyst Windows:
The late-November PDUFA cluster (KURA facing new competition, ARWR imminent on Nov 18, ASND) and mid-December decisions (MIST redemption story, AGIO, INVA, ALDX, RYTM) create multiple binary catalysts within a compressed timeframe. The ASH conference (Dec 6-9) adds data catalysts for hematology and CAR-T programs.

⚠️ Final Disclaimer

Data Sources: This analysis incorporates machine learning models trained on 15 years of biotech catalyst history, AI verification via web search, and publicly available information including SEC filings, clinical trial databases (ClinicalTrials.gov), company announcements, conference abstracts, and financial data. Web searches conducted October 31, 2025.

Limitations:

• Catalyst dates are estimates and may change without notice
• Clinical trial outcomes are inherently uncertain
• AI verification has limitations and may miss recent developments
• Financial data may not reflect most recent capitalization events
• Analysis focuses on top-tier opportunities; lower-scored candidates receive limited detail
• ML confidence scores reflect historical patterns, not future probability
• Not all publicly available information can be captured in automated systems

Scoring Methodology:
Each candidate was evaluated using a 4-factor framework: Catalyst Quality (35%), Clinical Merit (35%), Market Setup (20%), and Execution Context (10%). Scores are relative assessments based on available data, not absolute predictions of success.

No Professional Advice: This report does not constitute professional financial, investment, medical, or legal advice. All biotech investments carry high risk of loss. Clinical trials may fail, FDA decisions may surprise, and companies may dilute shareholders. Past performance does not guarantee future results.

Reader Responsibility: Readers are solely responsible for conducting independent research, consulting with qualified professionals (financial advisors, medical professionals, legal counsel), and making their own investment decisions. Do not rely solely on this report.

Forward-Looking Statements: This report contains forward-looking statements based on current expectations and assumptions. Actual results may differ materially from any projections or expectations. Catalyst dates may change, trials may be delayed, approvals may be denied, and companies may experience unexpected challenges.

Disclosure: The publisher may hold positions in discussed securities. This report is provided for informational and educational purposes only.

Report generated using ML + AI verification system
Next report: Friday, November 7, 2025